MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Bellerophon Therapeutics Company Profile (NASDAQ:BLPH)

Consensus Ratings for Bellerophon Therapeutics (NASDAQ:BLPH) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.67 (531.16% upside)

Analysts' Ratings History for Bellerophon Therapeutics (NASDAQ:BLPH)
Show:
DateFirmActionRatingPrice TargetActions
3/24/2016Cowen and CompanyInitiated CoverageBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/22/2016FBR & Co.Reiterated RatingOutperform$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/22/2016Leerink SwannLower Price TargetOutperform$11.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2015SunTrustInitiated CoverageBuy$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Bellerophon Therapeutics (NASDAQ:BLPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/16/2016        
5/10/2016Q116($0.65)($0.54)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/21/2016Q4($1.06)($0.82)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.94)($0.86)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/1/2015($2.16)($1.62)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Bellerophon Therapeutics (NASDAQ:BLPH)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.83)($0.42)($0.61)
Q2 20163($0.61)($0.46)($0.53)
Q3 20163($0.47)($0.39)($0.43)
Q4 20163($0.41)($0.37)($0.38)
(Data provided by Zacks Investment Research)
Dividend History for Bellerophon Therapeutics (NASDAQ:BLPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Bellerophon Therapeutics (NASDAQ:BLPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/17/2016Jonathan M PeacockCEOBuy5,000$1.37$6,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2015Jonathan M. PeacockCEOBuy20,300$2.75$55,825.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2015Jonathan M PeacockCEOBuy5,000$5.48$27,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2015Jonathan M PeacockCEOBuy5,560$8.69$48,316.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2015Daniel TasseDirectorBuy25,000$12.00$300,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2015Jonathan M PeacockCEOBuy20,800$12.00$249,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2015Linde North America, Inc.Major ShareholderBuy358,916$12.00$4,306,992.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2015Manesh NaiduInsiderBuy1,500$12.00$18,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Bellerophon Therapeutics (NASDAQ:BLPH)
DateHeadline
06/22/16 08:05 PMNew Broker Ratings For Bellerophon Therapeutics, Inc. (BLPH) - FTSE News
06/22/16 02:56 PMMedgenics, Inc. (NYSEMKT:MDGN) plummeted -13.78%: Bellerophon Therapeutics, Inc. (NASDAQ:BLPH), Kadant Inc ... - KC Register
06/20/16 02:52 PMBiotechnology Volatile Stocks: Prothena NASDAQ:PRTA), Bellerophon Therapeutics, Inc. (NASDAQ:BLPH), Onconova ... - KC Register
06/19/16 02:45 PMThis Weeks Broker Views For Bellerophon Therapeutics, Inc. (BLPH) - Fiscal Standard
06/18/16 07:33 AMBiotech Volatile Stocks: Bellerophon Therapeutics, Inc. (NASDAQ:BLPH), WAVE Life Sciences Ltd. (NASDAQ:WVE ... - KC Register
06/17/16 03:53 PMBELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/16/16 07:39 AMBellerophon Therapeutics Announces Enrollment of the First Patient in the INOvation-1 Phase 3 Clinical Trial for Pulmonary Arterial Hypertension (PAH) - [at noodls] - WARREN, N.J., June 16, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, announced today that the first subject has been enrolled in the Phase ...
06/16/16 07:17 AMBellerophon Therapeutics (BLPH) Enrolls First Patient in Phase 3 INOvation-1 - StreetInsider.com
06/13/16 03:06 PMDecliners to Watch: Bellerophon Therapeutics, Inc. (NASDAQ:BLPH), California Resources (NYSE:CRC), Dynamic ... - KC Register
06/13/16 03:06 PMStocks Earnings Review: Titan Pharmaceuticals Inc. (NASDAQ:TTNP), Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) - Beacon Chronicle
06/13/16 03:06 PMWhy Does Bellerophon Therapeutics Inc (NASDAQ: BLPH) Need So Much Cash? - Scibility Media
06/11/16 02:54 PMRecommendation Trends to See: Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) - News Oracle
06/10/16 11:22 AMGoPro, Inc. (NASDAQ:GPRO) Declined-1.45%: Bellerophon Therapeutics, Inc. (NASDAQ:BLPH), Farmers National ... - KC Register
06/10/16 11:22 AMNASDAQ Volatile Stocks: Bellerophon Therapeutics, Inc. (NASDAQ:BLPH), Biostar Pharmaceuticals, Inc. (NASDAQ ... - KC Register
06/09/16 02:54 PMFinjan Holdings, Inc. (NASDAQ:FNJN) surged 14.56%: Bellerophon Therapeutics, Inc. (NASDAQ:BLPH), Cohen ... - KC Register
06/04/16 11:22 AMBroker Watchlist: Bellerophon Therapeutics, Inc. (BLPH) - Share Trading News
06/03/16 11:26 AMBellerophon Therapeutics Inc (NASDAQ:BLPH) Stock Update & Estimates - Stock Tick Tock
05/31/16 02:56 PMBellerophon Therapeutics (NASDAQ:BLPH) went down -1.69%: Amber Road (NYSE:AMBR), Gaming Partners ... - KC Register - Bellerophon Therapeutics (NASDAQ:BLPH) went down -1.69%: Amber Road (NYSE:AMBR), Gaming Partners ...KC RegisterOn 10 May, Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) reported that, total Research and Development (R&D) expenses for the first quarter declined 46 percent to $5.1 million, from $9.5 million a year ago. The decrease in R&D was primarily due to ...
05/30/16 08:58 PMNext Weeks Broker Price Targets For Bellerophon Therapeutics, Inc. (BLPH) - Share Trading News - Next Weeks Broker Price Targets For Bellerophon Therapeutics, Inc. (BLPH)Share Trading NewsBellerophon Therapeutics, Inc. has a 50 day moving average of 1.79 and a 200 day moving average of 2.43. The stock's market capitalization is 15.63M, it has a 52-week low of 1.09 and a 52-week high of 9.72. The share price of the company (BLPH) was ...and more »
05/10/16 05:58 AMBellerophon Reports First Quarter 2016 Financial Results and Provides Business Update - [at noodls] - WARREN, N.J., May 10, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today reported financial results for the first quarter ended March ...
05/10/16 05:46 AMBellerophon Therapeutics posts 1Q loss -
03/21/16 08:44 AMEdited Transcript of BLPH earnings conference call or presentation 21-Mar-16 12:30pm GMT -
03/21/16 07:30 AMBellerophon Therapeutics Inc Earnings Call scheduled for 8:30 am ET today -
03/21/16 06:07 AMQ4 2015 Bellerophon Therapeutics Inc Earnings Release - Before Market Open -
03/21/16 05:37 AMBellerophon Reports 2015 Financial Results and Provides Business Update - [at noodls] - - Company Receives Final FDA Confirmation to Initiate Phase 3 Studies Using Next Generation INOpulse Device - - Management to Host a Conference Call Today at 8:30 a.m. ET - WARREN, N.J., March 21, 2016 ...
03/14/16 07:03 AMBellerophon Therapeutics to Hold Full Year 2015 Financial Results Conference Call on Monday March 21, 2016 - [GlobeNewswire] - WARREN, N.J., March 14, 2016-- Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company, today announced that it will release its full year 2015 financial results before the open of the ...
02/26/16 01:54 PMBellerophon Therapeutics, Inc. (BLPH) New Analyst Updates - Risers & Fallers - Bellerophon Therapeutics, Inc. (BLPH) New Analyst UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Bellerophon Therapeutics, Inc. (BLPH). According to the latest broker reports outstanding on Friday 26th of February, 2 analysts have a rating of “strong buy”, 2 ...
02/23/16 07:03 AMBellerophon Therapeutics Appoints Fabian Tenenbaum as Chief Financial Officer and Chief Business Officer - [GlobeNewswire] - WARREN, N.J., Feb. 23, 2016-- Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company, today announced the appointment of Fabian Tenenbaum as Chief Financial Officer and Chief Business ...
02/16/16 07:03 AMBellerophon Therapeutics Appoints Mary Ann Cloyd as an Independent Board Member - [GlobeNewswire] - WARREN, N.J., Feb. 16, 2016-- Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company, today announced the appointment of Mary Ann Cloyd as an independent director. Cloyd will also serve ...
02/09/16 07:03 AMBellerophon Therapeutics Announces Positive Data From the Final Analysis of the Phase 2 Long-Term Extension Study of INOpulse for Treatment of Pulmonary Arterial Hypertension - [GlobeNewswire] - WARREN, N.J., Feb. 09, 2016-- Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company, today announced positive data from the final analysis of the Company’ s Phase 2 long-term extension ...
02/03/16 07:03 AMBellerophon to Participate in LEERINK Partners 5th Annual Global Healthcare Conference - [GlobeNewswire] - WARREN, N.J., Feb. 03, 2016-- Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company, today announced that it will participate in LEERINK Partners 5 th Annual Global Healthcare Conference.. ...
01/21/16 07:26 AMBellerophon Therapeutics Announces Notice of Intention to Grant a European Patent Supporting Its INOpulse Program - [at noodls] - , (GLOBE NEWSWIRE) -- (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that the European Patent Office has issued a Notice of Intention to Grant a European Patent that provides ...
01/19/16 07:15 AMBellerophon Therapeutics Receives EC Certification for New INOpulse® Drug-Device Delivery System - [at noodls] - , (GLOBE NEWSWIRE) -- (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it has received EC Certification for its proprietary new, INOpulse® drug-device delivery system. This ...
12/13/15 10:25 AMThe Best and Worst IPO's of 2015 -
12/08/15 12:17 PMBELLEROPHON THERAPEUTICS, INC. Financials -
12/04/15 03:32 PMBELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an -
11/30/15 04:14 PMBELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
11/16/15 09:48 AMBELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement -
11/12/15 07:40 AMBELLEROPHON THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report -
11/12/15 05:26 AMBellerophon Reports 2015 Third Quarter Operational and Financial Results - [at noodls] - Bellerophon Reports 2015 Third Quarter Operational and Financial Results
10/01/15 07:17 AMDue Diligence Report: Phase 2 Success; Phase 3 the Real Test - [Accesswire] - NEW YORK, NY / ACCESSWIRE / October 1, 2015 / Vascular Bellerophon Therapeutics LLC. (NASDAQ: BLPH) a clinical-stage biotherapeutics company, announced that INOpulse(R), an inhaled treatment of nitric ...
09/30/15 03:08 PMSquashed Takeovers And Positive Test Results Propelling These Stocks Higher -
09/29/15 12:54 PMHedge Funds Disagree with the Market on One of These Two Falling Stocks -
09/25/15 02:30 PMBellerophon Presents Positive Interim Data on INOpulse -
09/25/15 01:46 PMThese Stocks Are Surging but See Which Ones Hedge Funds Think are Worth Investing In -
09/25/15 08:00 AMBellerophon Therapeutics, Inc. Conference Call to discuss Positive Data from Interim Analysis of Phase 2 Long-Term Extension Study of INOpulse(R) for Treatment of Pulmonary Arterial Hypertension scheduled for 9:00 am ET today -
09/25/15 07:01 AMBELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
09/24/15 04:04 PMBellerophon Therapeutics Announces Positive Data From Interim Analysis of Phase 2 Long-Term Extension Study of INOpulse(R) for Treatment of Pulmonary Arterial Hypertension - [at noodls] - Conference Call/Webcast to Be Held September 25, 2015 at 9:00am ET Interim Data Reinforces Earlier Phase 2 Data and Indicates Sustainability of Benefits for PAH Patients FDA Issues a Special Protocol Assessment ...
09/22/15 07:00 AMStockNewsNow.com Publishes New SNNLive Video Interview with Bellerophon Therapeutics, Inc. - [Marketwired] - StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Jonathan Peacock, Chairman and CEO of Bellerophon Therapeutics, Inc. , a clinical-stage biotherapeutics ...
09/17/15 03:32 PMBELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Direc -
About Bellerophon Therapeutics

Bellerophon Therapeutics logoBellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary and cardiac diseases. The Company has two programs in development. The first program, INOpulse, is based on its pulsatile nitric oxide delivery device. The Company is developing two product candidates under its INOpulse program: one for the treatment of pulmonary arterial hypertension (PAH) and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), which is in Phase II development. Its second program is bio absorbable cardiac matrix (BCM), which is in a placebo-controlled clinical trial. The Company is developing BCM for the prevention of cardiac remodeling, which leads to congestive heart failure following an ST-segment elevated myocardial infarction (STEMI).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BLPH
  • CUSIP:
Key Metrics:
  • Previous Close: $1.89
  • 50 Day Moving Average: $1.61
  • 200 Day Moving Average: $2.25
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $22.77M
  • Current Quarter EPS Consensus Estimate: $-1.84 EPS
Additional Links:
Bellerophon Therapeutics (NASDAQ:BLPH) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha